Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 441

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 2
Chunk 441
---
Vision® and Lumify® are (or were) the subjects of certain ongoing and past patent infringement proceedings, the Company cannot predict the magnitude or timing of a loss of exclusivity impact from PreserVision® and Lumify® as these are OTC products, and thus, the impact is not expected to be as significant as the LOE of a branded pharmaceutical product.See Note 19, “LEGAL PROCEEDINGS” to our audited Consolidated Financial Statements for further information.

66

RESULTS OF OPERATIONSOur operating results for the years 2024, 2023 and 2022 were as follows:Years Ended December 31,Change(in millions)2024202320222023 to 20242022 to 2023RevenuesProduct sales$4,774 $4,131 $3,746 $643 $385 Other revenues17 15 22 2 (7)4,791 4,146 3,768 645 378 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets) (Note 3)1,868 1,640 1,511 228 129 Cost of other revenues4 2 8 2 (6)Selling, general and administrative (Note 3)2,082 1,736 1,478 346 258 Research and development (Note 3)343 324 307 19 17 Amortization of intangible assets288 240 244 48 (4)Other expense, net44 74 13 (30)61 4,629 4,016 3,561 613 455 Operating income162 130 207 32 (77)Interest income15 15 6 — 9 Interest expense (Note 3)(399)(283)(146)(116)(137)Foreign exchange and other(12)(28)6 16 (34)(Loss) income before provision for income taxes(234)(166)73 (68)(239)Provision for income taxes(71)(82)(58)11 (24)Net (loss) income(305)(248)15 (57)(263)Net income attributable to noncontrolling interest(12)(12)(9)— (3)Net (loss) income attributable to Bausch + Lomb Corporation$(317)$(260)$6 $(57)$(266)A detailed